Exelixis is a Resilient Leader in the Field of Oncology Therapeutics
Our success in advancing clinical programs and establishing commercial product franchises has been fueled by our team’s unwavering belief in the science behind our molecules.
Exelixis’ flagship molecule, cabozantinib, is the origin of two commercial products (CABOMETYX® and COMETRIQ®). CABOMETYX is approved for patients with advanced renal cell carcinoma (RCC) and is currently the most widely used oral therapy for advanced RCC after prior antiangiogenic therapy.1 CABOMETYX is also the first and only tyrosine kinase inhibitor to demonstrate superior efficacy versus sunitinib in patients with first-line advanced RCC who were intermediate- or poor-risk per the International Metastatic Renal Cell Carcinoma Database Consortium criteria. COMETRIQ, our first commercial product, is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer. Exelixis’ third product, COTELLIC®, a formulation of cobimetinib, is a reversible inhibitor of MEK that is marketed under a collaboration with Genentech, a member of the Roche Group, and is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with ZELBORAF® (vemurafenib). Beyond our approved indications, these medicines are currently the focus of a robust clinical trial program, including collaborative studies to investigate multiple pathways and combination treatment regimens.
Partnering with Physicians to Put Patients First
Our commitment to developing best-in-class treatment regimens for patients is only part of Exelixis’ success equation. We maximize the value we bring into a physician’s office by making it as easy as possible to minimize patient burden. We collaborate with patients’ teams of healthcare providers on problem solving and deliver service in a way that aims to eliminate barriers and clear the hurdles so that those in need have access to our medicines.
- Internal data on file.